What Biogen's FY2025 10-K says: 12 signals
Biogen filed its latest 10-K with the SEC on Feb 6, 2026. It discusses joint venture, acquisition completed and capex increase.
Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn
- Filed
- Feb 6, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 7
What Biogen's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Biogen acquired Alcyone Therapeutics for ~$85M to gain new drug delivery device technology
Biogen completed the acquisition of Alcyone Therapeutics for its ThecaFlex DRx implantable device, paying $50M upfront with another $35M upon FDA approval.
$85M
Total consideration for Alcyone Therapeutics acquisition, including upfront and milestone payment.
medical deviceASOs
Biogen to consolidate into new HQ, reducing Massachusetts real estate footprint by 40%.
As part of a multi-year plan, Biogen is leasing a new 580,000 sq ft global headquarters in Cambridge, MA to integrate R&D, technical operations, and commercial teams.
40%
reduction of real estate footprint in Massachusetts
MIT Investment Management CompanyBioMed Realty
Biogen files for arbitration against partner Eisai over LEQEMBI commercialization in Europe.
Biogen is in a significant legal dispute with its key partner Eisai regarding the budget and commercialization plan for the Alzheimer's drug LEQEMBI in Europe.
Eisai
Biogen paid Stoke Therapeutics $165M upfront to co-develop and commercialize a rare disease drug
Biogen entered a major collaboration with Stoke Therapeutics, paying $165M to co-develop and commercialize zorevunersen for Dravet syndrome.
$165M
Upfront payment to Stoke Therapeutics for collaboration.
ASOStoke Therapeutics, Inc.
FDA rejects high-dose SPINRAZA application due to manufacturing and control (CMC) issues.
In September 2025, the FDA issued a Complete Response Letter (CRL) for a higher dose of SPINRAZA, citing deficiencies in the Chemistry Manufacturing and Controls (CMC) module.
Biogen plans 40% real estate reduction in MA and new 580,000 sq ft global HQ by 2028.
As part of a multi-year consolidation plan, Biogen is reducing its Massachusetts real estate footprint by 40% and building a new global headquarters.
40%
reduction of real estate footprint in Massachusetts
MIT Investment Management CompanyBioMed Realty
Biogen pays Vanqua Bio $70M upfront for rights to preclinical oral compound
Biogen entered a license agreement with Vanqua Bio, paying $70M upfront for exclusive worldwide rights to a preclinical oral C5aR1 antagonist.
$70M
Upfront payment to Vanqua Bio for license agreement.
Vanqua Bio, Inc.
Showing 7 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Biogen with the Signal API
One POST /v1/companies/enrich call with biogen.com returns Biogen 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Biogen 10-K
When did Biogen file its latest 10-K?
What does Biogen's latest 10-K say about acquisition completed?
Where can I find Biogen's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .